Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Corcept Therapeutics Incorporated
< Previous
1
2
Next >
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
May 01, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Completes Enrollment in Phase 4 CATALYST Trial
April 29, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
April 24, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
April 22, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
April 15, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
April 08, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
April 01, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
February 15, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
February 15, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
February 08, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Appoints Roberto Vieira as President, Oncology
January 29, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
January 08, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Court Finds Corcept Therapeutics’ Patents Not Infringed
January 02, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
November 01, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Appoints Monica Tellado as President, Emerging Markets
November 01, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)
October 26, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
October 25, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
August 02, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 26, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)
July 17, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer
June 27, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
May 03, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
April 26, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Therapeutics Announces Final Results of Tender Offer
April 05, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Therapeutics Announces Preliminary Results of Tender Offer
April 03, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Therapeutics Initiates CATALYST Clinical Trial
March 28, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common Stock
March 06, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate Update
February 28, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call
February 14, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation
February 13, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Tickers
CORT
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.